2024 Year End Report
Montreal, Quebec – December 23, 2024
As the year comes to a close, Thryv Therapeutics reflects on a transformative 2024 – a year defined by significant strides in advancing innovative therapies for people with unmet medical needs. From groundbreaking clinical milestones to impactful scientific contributions and collaborative partnerships, we are proud of the progress our team has made in addressing complex cardiovascular diseases such as Long QT Syndrome, heart failure, and atrial fibrillation. Our commitment to scientific excellence and improving patients’ lives has not only driven innovation but also set the stage for even greater accomplishments in the year ahead.
New Chief Medical Officer
Thryv Therapeutics proudly welcomed esteemed executive, Amy Sehnert, MD, as our new Chief Medical Officer in November 2024, marking a pivotal step in advancing our cardiometabolic product portfolio targeting SGK1. Dr. Sehnert, a pediatric cardiologist with expertise spanning genomics, cardiology, oncology, and maternal-fetal health, brings over 20 years of leadership experience in precision diagnostics and therapeutics. At MyoKardia, she played a key role in developing the FDA-approved Camzyos®, contributing to its $14 billion acquisition by Bristol Myers Squibb, where she subsequently led global cardiovascular programs.
Long QT Syndrome Program
2024 was a landmark year for our Long QT Syndrome (LQTS) program, with important advancements in both preclinical and clinical research. In September, the FDA granted Orphan Drug Designation (ODD) to LQT-1213 for the treatment of congenital LQTS, an important regulatory step for our LQTS program. We received positive topline results from our Wave I Part 2 clinical study, which demonstrated statistically significant reductions in QTc intervals in patients with congenital LQTS Types 2 and 3, paving the way for the pursuit of pivotal studies for LQT-1213 in LQTS Types 2 and 3 in 2025. We extend our gratitude to the SADS Foundation, the University of Rochester, Mayo Clinic, Stanford University and Massachusetts General Hospital and their investigators for their pivotal role in recruitment and to the patients for their participation. Full data from the Wave I Part 2 clinical study will be presented at a scientific conference in 2025.
2024 was also an impressive year for scientific presentations in the field of LQTS at major cardiology conferences. In March, we presented clinical results from our Wave I Part 1 study demonstrating LQT-1213 promotes significant reductions in QTc prolongation in a dofetilide-induced human model of LQTS, at the 2024 American College of Cardiology (ACC) Annual Meeting, and in May, we presented preclinical data demonstrating the attenuation of drug-induced QT-prolongation with our SGK1 inhibitors at the 2024 Heart Rhythm Society (HRS) Conference. In November, the results of preclinical research carried out by members of the European Joint Programme on Rare Diseases, demonstrating that our SGK1 inhibitor shortens action potential in LQT3 and LQT2 via inhibition of the late sodium current were presented at the 2024 the American Heart Association (AHA) Annual Scientific Sessions and won the prestigious 2024 AHA Paul Dudley White International Scholar Award.
We were also honored to participate in the 2024 International SADS Foundation Family Conference in November, where, over two inspiring days, we connected with and learned from people with LQTS, their families, advocates and researchers dedicated to improving the lives of those impacted by genetic arrhythmias like LQTS.
As we head into 2025, we look forward to initiating enrolment of our Wave I Part 3 clinical study in LQTS Type 1, advancing our pivotal clinical studies in LQTS Types 2 and 3, and launching our myQTwave non-interventional study to gather much needed quality of life data from people with LQTS Types 2 and 3, all with the aim of deepening our understanding of and developing transformative therapies for this life-threatening condition.
Heart Failure and Atrial Fibrillation Programs
In 2024, we completed dosing in our Phase 1 study of THRV-1268, our second SGK1 inhibitor, in both the SAD and MAD cohorts. The findings from this study will pave the way for future clinical investigations, targeting the abnormal electrophysiologic, structural and metabolic pathways involved in the pathogenesis of heart failure and atrial fibrillation in patients with underlying cardiometabolic conditions. Proof-of-concept clinical studies in these areas of high unmet need are planned for 2025.
We are proud to have had three posters of results from our pre-clinical studies presented at the 2024 AHA Annual Scientific Sessions: the first, demonstrating that our SGK1 inhibitor reduced hypertension in a salt-sensitive hypertension model of heart failure with preserved ejection fraction (HFpEF), the second, presented by Massachusetts General Hospital (MGH) and sponsored by Thryv, demonstrating that SGK1 inhibition attenuated left ventricular wall thickening and diastolic dysfunction in a model of HFpEF, and the third, demonstrating that SGK1 inhibition induces anti-fibrotic and anti-inflammatory responses, which may have therapeutic implications for cardiac fibrosis. These results highlight the dual potential of THRV-1268 to address cardiac structural and metabolic abnormalities, reinforcing Thryv’s position at the forefront of cardiometabolic innovation.
Looking Ahead
2024 has been a transformative year for Thryv Therapeutics, marked by milestones in LQTS, heart failure and atrial fibrillation research. These achievements reflect the dedication of our team, the support of our partners, and the trust of patients and families.
As we move into 2025, we remain steadfast in our mission to deliver transformative therapies, bringing hope to those affected by rare and life-threatening conditions.
Wishing all our supporters, patients, and families a healthy and happy new year!
Sincerely, Debra Odink
President & Chief Development Officer
